IRIS
BERTOLI, ADA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 22.959
EU - Europa 2.728
AS - Asia 2.421
SA - Sud America 430
AF - Africa 45
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 9
Totale 28.602
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 22.899
SG - Singapore 1.168
CN - Cina 507
IT - Italia 478
DE - Germania 416
BR - Brasile 365
SE - Svezia 329
UA - Ucraina 292
PL - Polonia 255
HK - Hong Kong 246
KR - Corea 225
IE - Irlanda 223
FR - Francia 197
RU - Federazione Russa 167
GB - Regno Unito 149
FI - Finlandia 87
VN - Vietnam 77
NL - Olanda 38
CA - Canada 29
IN - India 29
JP - Giappone 28
MX - Messico 26
AR - Argentina 23
ID - Indonesia 23
AT - Austria 22
CZ - Repubblica Ceca 20
BD - Bangladesh 19
ES - Italia 16
TR - Turchia 15
BE - Belgio 14
ZA - Sudafrica 14
IQ - Iraq 13
UZ - Uzbekistan 12
CL - Cile 10
AU - Australia 9
CH - Svizzera 9
VE - Venezuela 8
CO - Colombia 7
EC - Ecuador 7
IL - Israele 7
KG - Kirghizistan 7
PK - Pakistan 7
ET - Etiopia 6
EU - Europa 6
EG - Egitto 5
JO - Giordania 5
KE - Kenya 5
MA - Marocco 5
PY - Paraguay 5
AE - Emirati Arabi Uniti 4
IR - Iran 4
PH - Filippine 4
NP - Nepal 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AZ - Azerbaigian 2
BG - Bulgaria 2
BO - Bolivia 2
CY - Cipro 2
DK - Danimarca 2
JM - Giamaica 2
KZ - Kazakistan 2
LT - Lituania 2
LY - Libia 2
MN - Mongolia 2
NG - Nigeria 2
PE - Perù 2
PT - Portogallo 2
RO - Romania 2
SA - Arabia Saudita 2
TN - Tunisia 2
TW - Taiwan 2
AL - Albania 1
AO - Angola 1
BW - Botswana 1
BY - Bielorussia 1
CM - Camerun 1
EE - Estonia 1
GE - Georgia 1
GT - Guatemala 1
GY - Guiana 1
HN - Honduras 1
HU - Ungheria 1
LB - Libano 1
LK - Sri Lanka 1
MK - Macedonia 1
NZ - Nuova Zelanda 1
OM - Oman 1
QA - Qatar 1
RS - Serbia 1
SC - Seychelles 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 28.602
Salva come PNG Salva come JPEG
Città #
Woodbridge 6.679
Wilmington 6.056
Houston 4.712
Fairfield 714
Singapore 649
Chandler 589
Ann Arbor 528
Ashburn 413
Seattle 303
Beijing 245
Hong Kong 242
Jacksonville 242
Kraków 231
Cambridge 228
Rome 213
Dublin 207
Medford 156
New York 145
Santa Clara 121
Dearborn 112
Los Angeles 98
The Dalles 80
Zhengzhou 76
Lawrence 73
San Diego 53
Milan 52
Munich 46
Council Bluffs 43
São Paulo 40
Buffalo 39
Dallas 38
Menlo Park 36
Mülheim 35
Moscow 34
Nuremberg 31
Palo Alto 25
Ho Chi Minh City 24
San Francisco 24
Phoenix 23
London 21
Creede 20
Hanoi 20
Boardman 19
Jakarta 19
Tokyo 19
Warsaw 19
Redondo Beach 18
Colorado Springs 17
Falls Church 16
Montreal 16
Brooklyn 15
Chicago 15
University Park 15
Atlanta 14
Chennai 14
Denver 14
Nanjing 14
Olomouc 14
Orem 14
Stockholm 14
Brussels 13
Guangzhou 13
Helsinki 13
San Jose 12
Shanghai 12
Boston 11
Columbus 11
Lappeenranta 11
Norwalk 11
Rio de Janeiro 11
Bari 10
Amsterdam 9
Belo Horizonte 9
Dong Ket 9
Johannesburg 9
Salvador 9
Tashkent 9
Vienna 9
Redwood City 8
Verona 8
Frankfurt am Main 7
Hefei 7
Jinan 7
Mexico City 7
Mountain View 7
Seoul 7
Baghdad 6
Brno 6
Dhaka 6
Kunming 6
Magenta 6
Manchester 6
Querétaro 6
Amman 5
Brasília 5
Buenos Aires 5
Cedarhurst 5
Coventry 5
Florence 5
Manitou Springs 5
Totale 24.328
Salva come PNG Salva come JPEG
Nome #
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 557
Occupational HIV infection in a research laboratory with unknown mode of transmission: a case report 510
Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors 493
Characterization of drug-resistance mutations in HIV-1 isolates from non-HAART and HAART treated patients in Burkina Faso 481
The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients 479
Early antiretroviral treatment (eART) limits viral diversity over time in a long-term HIV viral suppressed perinatally infected child 473
Comparative Analysis of Drug Resistance Among B and the Most Prevalent Non-B HIV Type 1 Subtypes (C, F, and CRF02_AG) in Italy 472
Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients 468
Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro 467
Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice 464
Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naïve to antiviral drugs. 461
Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia 455
Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection 454
Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance. 454
Altered deoxyribonucleotide pools in T-lymphoblastoid cells expressing the multisubstrate nucleoside kinase of Drosophila melanogaster 453
Comparative evaluation of subtyping tools for the surveillance of newly emerging HIV-1 strains 451
Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors 450
Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy 450
Minor mutations in HIV protease at baseline and appearance of primary mutation 90M in patients for whom their first protease-inhibitor antiretroviral regimens failed 444
Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study 440
Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen 438
Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection. 437
A case of Italian HIV-2 infection: a genetic analysis 434
HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors 433
Specific HbsAg genetic determinants are associated with occult HBV infection in vivo and HbsAg detection 429
Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development 425
Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment 424
Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure 414
Temporal characterization of drug resistance associated mutations in HIV-1 protease and reverse transcriptase in patients failing antiretroviral therapy 411
Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen 410
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA Study Group 406
Docking Analysis and Resistance Evaluation of Clinically Relevant Mutations Associated with the HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors Nevirapine, Efavirenz and Etravirine 405
Key patterns of HBX and pre-S1/S2 mutations are involved in mechanisms underlying HBV-induced hepatocellular carcinoma in vivo 404
A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAART. 403
Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance 402
Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group 402
Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study 402
The contribution of oxidative stress in apoptosis of human-cultured astroglial cells induced by supernatants of HIV-1-infected macrophages 399
High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations 396
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? 395
Overlapping Structure of HBV genome and immune selecting pressure are the main driving forces for HBV evolution 394
Temporal change in the use of genotypic resistance testing over the years 1999--2003 394
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group 394
Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapy 392
Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA 392
Overlapping structure of HBV genome and immune selection pressure are critical forces modulating HBV evolution 382
Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome 377
Novel reverse transcriptase mutations specifically associated with selected anti-Hbv treatment can induce alterations and stop-codons in Hbv S antigen 377
Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels 377
Signature mutations in V3 and bridging sheet domain of HIV-1 gp120 are specifically associated with dual tropism and modulate the interaction with CCR5 N-terminus 363
HIV-1 non-B subtypes in Italy: a growing trend 363
Genotypic tropism testing in HIV-1 proviral DNA can provide useful information at low-level viremia 363
Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen 358
null 357
Plasma HIV RNA decline and emergence of drug resistance mutations among patients with multiple virologic failures receiving resistance testing-guided HAART 355
Dynamics and phylogenetic relationships of HIV-1 transmitted drug resistance according to subtype in Italy over the years 2000-14 353
Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy 344
The Lowest X4 Geno2Pheno-False Positive Rate Is Associated with Greater CD4-Depletion 340
Impact of HIV-1 tropism on the emergence of non-AIDS events in HIV-infected patients receiving fully suppressive antiretroviral therapy 339
The V118I mutation as a marker of advanced HIV infection and disease progression 337
Total HIV-1 DNA detection and quantification in peripheral blood by COBAS®AmpliPrep/COBAS® TaqMan® HIV-1 Test, v2.0 336
Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection 336
Recent transmission clustering of HIV-1 C and CRF17-BF strains characterized by NNRTI-related mutations among newly diagnosed men in central Italy 294
Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen 285
A Hyper-Glycosylation of HBV Surface Antigen Correlates with HBsAg-Negativity at Immunosuppression-Driven HBV Reactivation in Vivo and Hinders HBsAg Recognition in Vitro 236
HIV MDR is still a relevant issue despite its dramatic drop over the years 218
Key mutations in the C-terminus of the HBV surface glycoprotein correlate with lower HBsAg levels in vivo, hinder HBsAg secretion in vitro and reduce HBsAg structural stability in the setting of HBeAg-negative chronic HBV genotype-D infection 138
Cryptic HBV replicative activity is frequently revealed in anti-HBC-positive/hbsag-negative patients with HIV infection by highly sensitive molecular assays, and can be predicted by integrating classical and novel serological HBV markers 134
Highly Sensitive HBsAg, Anti-HBc and Anti HBsAg Titres in Early Diagnosis of HBV Reactivation in Anti-HBc-Positive Onco-Haematological Patients 133
Droplet digital PCR assay as an innovative and promising highly sensitive assay to unveil residual and cryptic HBV replication in peripheral compartment 133
Long-term SARS-CoV-2 infection associated with viral dissemination in different body fluids Including bile in two patients with acute cholecystitis 128
Genetic Determinants in a Critical Domain of NS5A Correlate with Hepatocellular Carcinoma in Cirrhotic Patients Infected with HCV Genotype 1b 106
HBeAg Levels Vary across the Different Stages of HBV Infection According to the Extent of Immunological Pressure and Are Associated with Therapeutic Outcome in the Setting of Immunosuppression-Driven HBV Reactivation 106
An HIV Type 2 Case Series in Italy: A Phylogenetic Analysis 105
HIV-1 transmitted drug resistance in newly diagnosed individuals in Italy over the period 2015-21 97
Comparison of Different HIV-1 Resistance Interpretation Tools for Next-Generation Sequencing in Italy 91
Temporal trend of drug-resistance and APOBEC editing in PBMC genotypic resistance tests from HIV-1 infected virologically suppressed individuals 90
Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings 85
Genotypic HIV-1 tropism determination might help to identify people with exhausted treatment options and advanced disease 84
Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice 80
Infection Rate of Respiratory Viruses in the Pandemic SARS-CoV-2 Period Considering Symptomatic Patients: Two Years of Ongoing Observations 70
Unexpected rise in the circulation of complex HBV variants enriched of HBsAg vaccine-escape mutations in HBV genotype-D: potential impact on HBsAg detection/quantification and vaccination strategies 66
Prevalence of hepatitis D virus infection in Central Italy has remained stable across the last 2 decades with dominance of subgenotypes 1 and characterized by elevated viral replication 62
Genetic heterogenicity of HIV-1 protease in drug-naive and drug-treated HIV-positive patients 59
Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings 59
Stable temporal trend of HDV seroprevalence in central Italy across the last two decades with the circulation of HDV sub-genotypes 1 inducing different inflammatory stimuli 57
Factors predictive of multinucleoside analogue-resistance mutations in an unselected cohort of HAART-failed patients. 54
Factors predictive of virological response after genotyping resistance test (GRT): data from an unselected cohort 50
Evaluation of HIV-1 integrase variability by combining computational and probabilistic approaches 49
Prevalence and phenotypic susceptibility to doravirine of the HIV-1 reverse transcriptase V106I polymorphism in B and non-B subtypes 46
Cross-resistance among NNRTIs: evaluation of the option of recycling Efavirenz after Nevirapine failure 46
Identification of the Minimal Conserved Structure of the HIV-Reverse Transcriptase under the Presence and Absence of Drug Pressure 35
Temporal characterization of frequency of drug-resistance associated mutations in the HIV-1 protease and reverse transcriptase 33
Time to detection and loss of M184 genotypic mutation among HIV patients treated with 3TC and failing an HAART regimen 29
Using a database of HIV patients undergoing genotypic resistance test after HAART failure to understand the dynamics of M184V mutation 28
Totale 28.954
Salva come PNG Salva come JPEG
Categoria #
all - tutte 67.495
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 67.495
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.649 0 0 0 0 0 413 544 350 80 77 128 57
2021/20221.111 59 77 106 65 33 88 46 40 207 81 44 265
2022/20231.445 119 136 113 186 104 288 87 138 117 47 76 34
2023/2024437 57 10 30 20 45 98 22 20 10 20 5 100
2024/20252.321 92 501 243 116 99 132 299 120 258 134 152 175
2025/20261.770 315 149 399 386 391 130 0 0 0 0 0 0
Totale 28.954